I'm LongbridgeAI, I can summarize articles.CASI Pharmaceuticals has closed the second tranche of its US$20 million convertible note financing, issuing a new US$5 million note with a 12% interest rate, maturing in 36 months. The note can be converted into shares at a price capped between US$1 and US$2. Analysts rate CASI stock as a Hold with a $1.00 price target, citing poor financial performance and high leverage. CASI focuses on developing treatments for organ transplant rejection and autoimmune diseases.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from CASI Pharmaceuticals ( (CASI) ) is now available.
On January 13, 2026, CASI Pharmaceuticals announced it had closed the second tranche of its previously arranged US$20 million convertible note financing with ETP Global III Fund LP, a partnership controlled by Dr. Wei-Wu He, issuing a new US$5 million convertible note. The note carries a 12% annual interest rate, matures in 36 months, and may be converted into ordinary shares either at the company’s option at maturity or at the investor’s option after 90 days, with the conversion price set to a five-day volume-weighted average and capped between US$1 and US$2 per share, a structure that provides CASI with near-term funding while potentially diluting existing shareholders depending on future share price performance.
The most recent analyst rating on (CASI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., listed on Nasdaq, is a clinical-stage biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody intended for patients with organ transplant rejection and autoimmune diseases. The company operates primarily in drug development, targeting niche, high-need immunology and transplant-related indications within the global biopharma market.
Average Trading Volume: 32,903
Technical Sentiment Signal: Sell
Current Market Cap: $17.04M
Learn more about CASI stock on TipRanks’ Stock Analysis page.